Palouse Capital Management Inc. Has $236,000 Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Palouse Capital Management Inc. lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 80.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 481 shares of the medical research company’s stock after selling 2,003 shares during the quarter. Palouse Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $236,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Assetmark Inc. raised its holdings in shares of Thermo Fisher Scientific by 22.9% during the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after acquiring an additional 7,023 shares during the period. Mackenzie Financial Corp increased its holdings in Thermo Fisher Scientific by 29.4% during the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock worth $134,130,000 after purchasing an additional 62,790 shares in the last quarter. North Dakota State Investment Board acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $7,505,000. Quadrant Capital Group LLC lifted its holdings in shares of Thermo Fisher Scientific by 30.9% in the third quarter. Quadrant Capital Group LLC now owns 14,277 shares of the medical research company’s stock valued at $6,924,000 after purchasing an additional 3,369 shares in the last quarter. Finally, EdgePoint Investment Group Inc. boosted its position in shares of Thermo Fisher Scientific by 5.0% during the third quarter. EdgePoint Investment Group Inc. now owns 1,388,662 shares of the medical research company’s stock worth $673,529,000 after buying an additional 65,597 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 2.4%

Shares of Thermo Fisher Scientific stock opened at $513.53 on Thursday. The stock has a market cap of $190.84 billion, a P/E ratio of 28.23, a P/E/G ratio of 2.22 and a beta of 0.87. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $403.36 and a 12-month high of $643.99. The business’s 50 day moving average is $473.08 and its 200-day moving average is $518.47.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same period last year, the business earned $5.15 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of recent research reports. Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their price target for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 target price for the company. Stifel Nicolaus decreased their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Finally, Morgan Stanley reissued an “overweight” rating and set a $620.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $605.09.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.